It is possible to manufacture monoclonal antibodies using traditional methods, but the challenges inherent in bispecific antibodies such as low titer, mismatched chains, unwanted fragments and higher aggregation levels require a heightened analytical focus on clonal cell selection. Here, Stuart Jamieson and Alice Harrison at Lonza discuss high-throughput analytical strategies that enable right-first-time selection of the optimal clone to take through to clinical manufacture.
Innovations in antibody design have led to an increasingly diverse range of therapeutic molecules in development including bispecific antibodies (bsAbs). Eight bispecific antibodies have been approved by the European Medicines Agency, including four novel products in 2022.1 Such rapid expansion provides opportunities for significant therapeutic advancement.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries ā register to receive the recording post-event.
Ā
In contrast to natural antibodies, bsAbs are highly engineered therapeutic molecules designed to bind to two antigen epitopes simultaneously. Innovative bsAb designs, as highly targeted medicines, hold the promise of changing the way we treat cancer and other diseases.2 A bsAb can have clinical advantages over conventional monoclonal antibodies (mAbs) including targeting functionally interrelated checkpoint inhibitors, directing immune responders to cancer cells, enhancing specificity and decreasing off-target toxicity. While the first successful approvals of bsAbs underscore the potential of this class of antibodies, they also highlight the manufacturing challenge; the first bsAb, blinatumomab, took 13 years to advance through clinical development.3 As bsAbs are highly engineered and often comprise three or more polypeptide chains, they have increased production challenges compared to mAbs. These challenges include low product yields, erroneous chain assembly, high aggregate levels and adverse fragmentation.
As bsAbs are highly engineered and often comprise three or more polypeptide chains, they have increased production challenges compared to mAbsā
To achieve accelerated timelines and overcome bsAb manufacturing challenges, a focus on critical path activities is required.4 One of the first activities to fall onto the critical path, and potentially cause substantial drug development delays, is clone selection. Rapid development of clonal cell lines is required to facilitate material manufacture for non-clinical toxicological studies, and master cell bank (MCB) creation to enable clinical manufacture. Traditionally, preparing the MCB can be time consuming and expensive, taking six months or more. The success of the MCB choice impacts both regulatory approval prospects and the manufacturability of the bsAb. A delicate balance between the high-resource obligations of extensive testing and the importance of the choice means manufacturers are motivated to employ improved strategies for clone screening and characterisation at the earliest stages.
Rapid development of clonal cell lines
The development pathway for mAbs has been established over many yearsā
The aim of clonal bsAb cell line development is to identify a single clonal line that stably secretes gram-per-litre quantities of product with desired critical quality attributes (CQAs). For a bsAb these attributes include correctly assembled product in addition to minimal aggregation and fragmentation. While construct design optimisation and improved transfection technologies can partially overcome these challenges, as discussed in an earlier article, enhanced cell line development strategies and analytical screening improve expression profiles and yield of bsAbs.5
Cell line development workflows can be intricate and the development pathway for mAbs has been established over many years. Chinese hamster ovary (CHO) cells are the most commonly used mammalian expression hosts. Platforms for CHO cell line establishment are routinely optimised to facilitate robust, scalable production, which can be tailored to achieve clinicallyārelevant postātranslational modifications. Once an expression construct is selected, cells are transfected, stable pools generated, clonal cells isolated and monoclonality is tested. After monoclonality confirmation, cells are expanded, productivity is assessed and clone stability is confirmed. This process is outlined in Figure 1.
Figure 1: Overview of the cell line development process at Lonza.
In recent years significant improvements in automation of cell line development have reduced timelines for demonstrating productivity and clonality of lead cell lines from months to weeks. Technologies include advanced platforms like ClonePixĀ® with monoclonality assurance, CellCelectorĀ®, BeaconĀ® and Cyto-MineĀ®, which automate cloning, productivity screening and, in some cases, identify clones with increased aggregation.6 At Lonza the Beacon system is used to rapidly screen and isolate thousands of highly productive clones generated using Lonzaās GSĀ XceedĀ® PiggyBacĀ® expression system. DuringĀ aĀ study performed at Lonza, approximatelyĀ 3,000 individual cells from a polyclonal pool were isolated into pens on an optofluidic chip. The pens were automatically screened for monoclonality and pens containing polyclonal populations were rejected. As the cells were developed, their productivity and growth characteristics were continually monitored. UsingĀ this data, it was possible to select a lead cell line that was scalable and produced 8 g/l across 15mlĀ to 200l (see Figure 2).
Figure 2: Assessment of thousands of individual clones using the Beacon Spotlight Assay for binding of the Fc antibody domain. Polyclonal pool material is sorted into monoclonal populations for selection of a lead clone and material supply for toxicological studies.
Product quality screening during clonal cell line selection
The increasing variety of bsAb formats under development leads to a propensity for undesirable common molecule characteristics to occur in varying levels across the clones. Therefore, it is necessary to evaluate CQAs during clone selection. It is beneficial to go beyond the standard analytical toolbox and perform additional testing. By conducting this analysis, it is possible to identify clones with an optimal balance of performance, ie those that are high yielding but also have good CQAs and low levels of product-related impurities. Selection of the clone with the best characteristics can reduce the purification challenge, potentially leading to more efficient production process and better overall yield compared to selecting on titer alone.
Selection of the clone with the best characteristics can reduce the purification challenge, potentially leading to more efficient production process and better overall yield compared to selecting on titer aloneā
While it is possible to perform certain analysis, as discussed below, without the need to purify samples, other methods require partial purification of the clonal supernatants. This purification needs to primarily reduce the level of host cell impurities and retain the product-related ones in order to allow a comparison of the clones and the product CQAs. To facilitate the selection of high-performing clonal cell lines, a rapid purification method that supports analysis of a large number of cell line samples is required. Fortunately, high-throughput automated liquid handling purification platforms can be utilised. These platforms employ affinity chromatography to capture and collect the product and product-related species for further analysis.
Rapid analytical strategies for clone assessment
The most advanced cloning and screening platforms provide initial screening capabilities and estimates of productivity. However, they are not, for the most part, capable of assessing highly relevant CQAs for bsAbs, such as chain pairing, fragmentation and aggregation.
Analytical testing of bsAbs is more challenging than standard mAbs due to the requirement for product-specific methods to be employed. TheĀ need for high-throughput (HT) analytics to address these challenges is clear. This need has led to advancements in HT mass spectrometry (MS) techniques, including:
affinity-native protein A-MS for assessment of chain pairing and fragmentation withoutĀ purification7
competitive binding-MS for analysis of multiple PQAs and rapid HT N-glycan analysis using combined LC/MS
capillary electrophoresis (CE) for HT glycan screening of clones.8
Rapid establishment of toolbox methods for chain mispairing, such as Lonzaās RP-HPLC MS chain pairing technology,4 can provide key insights into the quality of bispecific assembly at a critical stage of clonal selection, while minimising impact upon project timeline.
Rapid establishment of toolbox methods for chain mispairing, such as Lonzaās RP-HPLC MS chain pairing technology,4 can provide key insights into the quality of bispecific assembly at a critical stage of clonal selection, while minimising impact upon project timeline.”
A key functional advantage of bsAbs over mAbs is the ability to bind two separate antigens. It is critical to establish dual specificity, and in doing so confirm correct assembly, early in the cell development process. A barrier to this has been the requirement for low-throughput binding and activity assays, such as enzyme-linked immunosorbent assays (ELISAs) and cell-based potency assessments. However, recent advances in biolayer interferometry (BLI) and surface plasmon resonance (SPR) sensor systems have overcome these barriers.9 An HT method was developed at Lonza for assessment of chain pairing and bsAb functionality; the binding of the antigens demonstrates whether each bsAb functional domain is active, while the ratio of the binding relates to the chain assembly. This technology enables ranking of clones based on correct molecular assembly. Including a control antibody for calibration curve generation and using an HTP surface plasmon resonance instrument, allows information on binding quality, titer and chain pairing of potentially hundreds of clones within a single automated experiment. The use of pre-established technologies, such as a CM5 protein A sensor surface, permits rapid method establishment and a minimal requirement for assay optimisation. An SPR study performed at Lonza in which bsAb clones were selected for further assessment, demonstrated the method enables chain pairing assessment, shown in Figure 3, where clones that yield antibodies with binding ratios close to one were correctly assembled. This allows rapid information generation to select the most suitable candidate as a lead clone.
Figure 3: Assessment of bsAb chain assembly using surface plasmon resonance. An assay was developed to establish assembly of Fc containing bispecific molecules. Binding levels are monitored and the ratio between the binding of antigen 1 and antigen 2 indicates incorrectly assembled molecules, where a ratio of 1 indicates a correctly assembled heterodimer.
Further work in this area could enable not only a qualitative binding assessment and quantitative titer and chain pairing ranking, but also a detailed kinetic characterisation and potency determination of large numbers of bispecific clones in a single experiment.
Future perspectives on cell line selection
Rapid selection of a single master cell line expressing more complex antibody molecules from thousands of possible clones lends itself to the application of machine learning tools and software-assisted cell line selection”
Speed, performance and quality are all important drivers for a bsAb cell line development strategy to ensure that a high value clone is selected within an accelerated timeline and to reduce the manufacturing challenge. In recent years, enabling technologies have led to a large reduction in workflows as well as incorporation of HT analytics to help make informed selection decisions. This is helping us move towards a fully automated workflow, including product relevant HT analytics and integrated data analysis. In addition, the challenge of rapid selection of a single master cell line expressing more complex antibody molecules, such as bsAbs, from thousands of possible clones lends itself to the application of machine learning tools and software-assisted cell line selection. There is a growing move away from established, conventional cell culture and analysis techniques towards more digitally immersive cell development platforms. Future platforms will be built upon laboratory implementation of nanofluidic technology, for single cell level data collection, and cell line selection trough the predictive capabilities of machine-learning algorithms. If utilised appropriately such platforms will revolutionise clone selection and the creation of the MCB for bispecific and complex protein products, delivering increased efficiency. This will ultimately propel improved performance via precise decision making and enhanced control of quality attributes. Ā
About the author
Stuart Jamieson is a Global Technical & CMC Director for Downstream Development at Lonza in Slough, UK. He has over 20 yearsā experience in protein purification and analysis, process development, scaleup and clinical manufacture for early- to late-phase products gained working with Lonza, CPI Biologics and another major CDMO. Stuartās expertise spans providing technical leadership for a diverse range of product types and is underpinned by a degree in biochemistry and a PhD in biochemistry and structural biology from The University of Sheffield, UK.
Alice Harrison is the Global Technical Director (CMC & Analytics) at Lonza, in Slough, UK and joined the company in 2022. Prior to that Alice worked within the biopharmaceutical industry for over 20 years, where she founded and led businesses supporting the development of antibody and complex protein therapeutics, gaining experience in large molecule analysis and an in-depth understanding of the bioanalytical challenges of complex molecule programmes. Her experience is supported by a degree in chemistry from Queen Mary College (University of London, UK) and a DPhil in molecular immunology from the University of Oxford, UK.
Lim SM, Pyo KH, Soo RA, Cho BC. The promise of bispecific antibodies: Clinical applications and challenges. Cancer Treat Rev. 2021 Sep;99:102240. Available at: doi.org/10.1016/j.ctrv.2021.102240
Friberg G, Reese D. Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL). Ann Oncol. 2017 Aug 1;28(8):2009-2012. Available from: doi:10.1093/annonc/mdx150.
Jamieson S, Harrison A. Accelerating timelines for development and manufacture of multi-specific antibodies. European Pharmaceutical Review 2022;27(04):48.
Jamieson S, Harrison A. Rapid method development to overcome challenges of bi-specific antibody purification. European Pharmaceutical Review 2022; 27 (03);6.
Tejwani V, Chaudhari M, Rai T, Sharfstein ST. Highāthroughput and automation advances for accelerating singleācell cloning, monoclonality and early phase clone screening steps in mammalian cell line development for biologics production. Biotechnology Progress. 2021;37(6).
Sawyer WS, Srikumar N, Carver J, et al. High-throughput antibody screening from complex matrices using intact protein electrospray mass spectrometry. Proceedings of the National Academy of Sciences. 2020;117(18):9851ā6.
Goel M, Srivastava R, Gupta S, et al. 2N-Glycan Analysis: Rapid preparation and screening of biosimilar candidates by LC/MS and CE. Application Note: 5994-0943EN.pdf (agilent.com)
Li H, Kumaraswamy S, Rubio-Marrero E, et al. Application Note: A rapid method to quantitatively screen bispecific antibodies using Protein A and OctetĀ® His1K Biosensors. sartorius.com.
X Tao W, Ahmed W, Guo M, et al. Selection of high-producing clones by a relative titer predictive model using image analysis. Ann Transl Med. 2021 Jul;9(14):1144. Available at: doi: 10.21037/atm-21-2822.
This article featured in European Pharmaceutical Review Issue 6 2022.Ā Sign up for free to receive future issues!
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as āNecessaryā are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies āAdvertising & Targetingā, āAnalyticsā and āPerformanceā, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to āEnabledā or āDisabledā, then click āSave and Acceptā. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving āAlways Onlineā until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving āAlways Onlineā until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.